Decera Clinical Education Oncology Podcast
di Decera Clinical Education
TROP2-Directed ADCs in NSCLC: Current Evidence, Emerging Therapies…
Informazioni su questo podcast
Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.
Episodi
I 20 episodi più recenti su 274
- TROP2-Directed ADCs in NSCLC: Current Evidence, Emerging Therapies, and Future Treatment Strategies · 29 min · Episodio 278In this podcast, experts discuss the evolving role of TROP2-directed antibody–drug conjugates (ADCs) in NSCLC, highlighting current clinical applications, emerging efficacy and…
- Experts Discuss Key Topics in Treatment for Newly Diagnosed Multiple Myeloma · 24 min · Episodio 276Listen to expert faculty discuss the evolving role of quadruplet therapy in newly diagnosed multiple myeloma, with an emphasis on treatment selection across transplant-eligible…
- PARP Inhibitors in Metastatic Prostate Cancer: Biomarker Testing, Treatment Strategies, and Toxicity Management · 27 min · Episodio 275In this podcast, experts discuss the evolving role of PARP inhibitors in metastatic prostate cancer, with a focus on the biologic rationale for PARP inhibition in tumors with HRR…
- Experts Discuss Sequencing of Therapies for Relapsed/Refractory Multiple Myeloma · 29 min · Episodio 274In relapsed/refractory multiple myeloma, prior therapy can affect subsequent treatment efficacy, highlighting the importance of thoughtful sequencing and consideration of…
- ASCO 2026 Updates in Metastatic Breast Cancer · 19 min · Episodio 273In this podcast, experts review practice-informing data presented at the ASCO 2026 annual conference that may reshape treatment decisions in metastatic breast cancer. The…
- Evolving Role of B7-H3–Directed ADCs in the Extensive-Stage Small-Cell Lung Cancer Treatment Landscape · 35 min · Episodio 272The care of patients with extensive-stage (ES) small-cell lung cancer (SCLC) continues to evolve with the continuous release of new clinical evidence. Listen to this podcast with…
- Targeting CDH6 in Platinum-Resistant Ovarian Cancer: Emerging ADCs, Biomarkers, and Sequencing · 29 min · Episodio 271In this podcast episode, experts discuss the scientific rationale and emerging clinical evidence for targeting CDH6 in platinum-resistant ovarian cancer, with a focus on…
- ASCO 2026 Updates in Early Hormone Receptor–Positive Breast Cancer · 9 min · Episodio 270In this podcast, experts review 2 of the most important studies presented at the ASCO 2026 annual conference that inform treatment decisions for patients with early-stage hormone…
- CELMoDs on the Horizon: A New Chapter in Lymphoma Care · 23 min · Episodio 269In this podcast, 2 experts explore the evolving role of CELMoD-based strategies in lymphoma, with a focus on the biologic mechanisms and emerging clinical evidence for…
- Experts Discuss Health Disparities and Equitable Care Strategies in Multiple Myeloma · 14 min · Episodio 267Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss health disparities and equitable care strategies in multiple myeloma, including treatment for underserved…
- Experts Discuss CELMoD Agents for Multiple Myeloma · 26 min · Episodio 268Listen to expert faculty as they discuss the use of CELMoD agents to manage multiple myeloma, including a recent approval, mechanism of action and differentiation from IMiDs…
- Optimizing Oral Targeted Therapies for HR+/HER2- Breast Cancer · 33 min · Episodio 265Oral targeted therapies are increasingly used across early-stage and metastatic HR-positive/HER2-negative breast cancer, but optimal use can be complicated by disease setting…
- TGCT Today: Understanding Diagnosis, Treatment, and Long-term Care · 36 min · Episodio 266Tenosynovial giant cell tumor (TGCT) can present significant diagnostic and management challenges, particularly in patients with diffuse disease where symptoms, functional…
- Optimizing Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Pharmacist Perspectives · 29 min · Episodio 264This podcast examines evidence guiding the use of anti-CD38–based therapy in smoldering and newly diagnosed multiple myeloma, including risk stratification, transplant…
- New and Emerging Targeted Therapies for Patients With DLBCL · 39 min · Episodio 263The management of patients with DLBCL is rapidly changing with several targeted agents across different drug classes on the near horizon. Experts discuss the potential utility of…
- Changing the Paradigm in HER2-Positive Early Breast Cancer · 25 min · Episodio 262The DESTINY-Breast11 and DESTINY-Breast05 trials of trastuzumab deruxtecan are changing the paradigm for HER2-positive early breast cancer, but the broad new indications leave…
- Recent Advances, Future Directions, and Ideas on Integrating CELMoDs Into The Care Of Patients With Myeloma · 18 min · Episodio 255Listen to this podcast to hear Sagar Lonial, MD, FACP, FASCO, and Mohamad Mohty, MD, PhD, discuss recent advances, future directions, and the integration of novel protein…
- To Treat or Not to Treat: Assessing Risk and Treatment Options in High-Risk SMM · 48 min · Episodio 261The care of patients diagnosed with smoldering multiple myeloma (SMM) continues to evolve with the rapid release of new clinical evidence. Listen to this podcast with 2 experts…
- Unmet Needs, Recent Advances, and Expert Insights on Integrating TROP-2 ADCs Into the Care of Patients With TNBC · 22 min · Episodio 260For patients with metastatic triple-negative breast cancer (TNBC) who are not candidates for immunotherapy, treatment selection remains challenging because of aggressive disease…
- Optimizing Bispecific Antibody Safety and Care Coordination From the Pharmacy in RRMM · 31 min · Episodio 259Bispecific antibody therapy continues to rapidly change the care of patients with relapsed/refractory multiple myeloma (RRMM). In this podcast, learners will hear 2 oncology…








